Loading…
Cognition Therapeutics, Inc. is projected to rise to $1.02 by 2027, a +15% move from its current price of $0.8896. CGTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8545 | $0.8903 | $0.9276 | +0.08% |
| Aug 6 | $0.8408 | $0.891 | $0.9443 | +0.16% |
| Aug 7 | $0.8305 | $0.8918 | $0.9575 | +0.24% |
| Aug 8 | $0.8221 | $0.8925 | $0.9689 | +0.32% |
| Aug 9 | $0.8148 | $0.8932 | $0.9791 | +0.40% |
| Aug 10 | $0.8084 | $0.8939 | $0.9885 | +0.49% |
| Aug 11 | $0.8025 | $0.8946 | $0.9973 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8025 | $0.8946 | $0.9973 | +0.57% |
| Week 2 | $0.7715 | $0.8997 | $1.05 | +1.14% |
| Week 3 | $0.7496 | $0.9048 | $1.09 | +1.71% |
| Week 4 | $0.7322 | $0.9099 | $1.13 | +2.29% |
| Week 5 | $0.7177 | $0.9151 | $1.17 | +2.87% |
| Week 6 | $0.7052 | $0.9203 | $1.20 | +3.45% |
| Week 7 | $0.6942 | $0.9255 | $1.23 | +4.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting age-related neurodegenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
CGTX is the stock ticker for Cognition Therapeutics, Inc. The current price is $0.9491 and the market cap is $84.94M, with a rank of 4301.
The forecast shows a long-run price path with a rising average and sizable upside by 2050: 2026 avg $0.9491, 2026 min $0.595, 2026 max $1.43; 2027 avg $1.08, 2027 max $1.61; 2028 avg $0.9589, 2028 max $1.52; 2029 avg $1.37, 2029 max $2.28, ROI 44.4%; 2030 avg $1.72, 2030 max $2.99, ROI 81.7%; 2031 avg $2.12, 2031 max $3.80, ROI 123.1%; 2032 avg $2.63, 2032 max $4.87, ROI 177%; 2033 avg $2.54, 2033 max $4.84, ROI 167.8%; 2034 avg $2.68, 2034 max $5.22, ROI 182.1%; 2035 avg $2.78, 2035 max $5.54, ROI 192.5%; 2040 avg $5.09, 2040 max $11.17, ROI 436.1%; 2050 avg $9.14, 2050 max $21.01, ROI 862.6%.
The long-run price outlook indicates a bullish trajectory with rising averages and high upside by 2040 and 2050 under bullish sentiment.
A major floor 59.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 88.8% above — a clean break opens room to run.
A major ceiling 118.5% above — clearing it would confirm fresh momentum.
Key CGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.916 | Sell | $0.9129 | Sell |
| MA 10 | $0.9371 | Sell | $0.9365 | Sell |
| MA 20 | $0.9826 | Sell | $0.9895 | Sell |
| MA 50 | $1.15 | Sell | $1.08 | Sell |
| MA 100 | $1.12 | Sell | $1.14 | Sell |
| MA 200 | $1.28 | Sell | $1.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.15 | Neutral |
| Stoch RSI (14) | 2.15 | Buy |
| CCI (20) | -108.32 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -6.22 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.93 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 28.26 | Buy |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.89 | Sell |
| ADX (14) | 19.46 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL.
RSI (RSI14) is 40, with a 50-day moving average (SMA50) of $1.21 and a 200-day moving average (SMA200) of $1.32. Support is at $0.949 and resistance at $1.68. The thirty-day range runs from $0.66 to $1.36.
Annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.595 | $0.8896 | $1.24 | 0% | Neutral | |
| $0.7792 | $1.02 | $1.44 | +15% | Neutral | |
| $0.6863 | $0.9431 | $1.40 | +6% | Neutral | |
| $0.8145 | $1.16 | $1.80 | +31% | Bullish | |
| $0.9744 | $1.44 | $2.30 | +62% | Bullish | |
| $1.14 | $1.74 | $2.86 | +95% | Bullish | |
| $1.29 | $2.02 | $3.41 | +127% | Bullish | |
| $1.29 | $2.08 | $3.59 | +133% | Bullish | |
| $1.33 | $2.19 | $3.88 | +147% | Bullish | |
| $1.30 | $2.20 | $3.97 | +148% | Bullish | |
| $1.99 | $3.81 | $7.44 | +328% | Bullish | |
| $3.00 | $6.66 | $14.61 | +649% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.595 | $0.8896 | $1.09 | +0.00% |
| September 2026 | $0.7857 | $0.9429 | $1.17 | +5.99% |
| October 2026 | $0.7896 | $0.9576 | $1.21 | +1.55% |
| November 2026 | $0.7649 | $0.9355 | $1.20 | -2.30% |
| December 2026 | $0.776 | $0.9567 | $1.24 | +2.26% |
Click any year to see its month-by-month CGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cognition Therapeutics, Inc.'s 2026 outlook centres on $0.8896, within a $0.595 to $1.24 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGTX could reach as high as $1.44, with a base case around $1.02 and support toward $0.7792 — roughly +15% from $0.8896. Price action looks broadly range-bound.
Expect CGTX to range from $0.6863 to $1.40 through 2028. The $0.9431 average target implies a +6% move from current prices. That is -8% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CGTX price prediction for 2029 points to an average of $1.16 (low $0.8145, high $1.80) — a potential gain of +31% on today's $0.8896. Momentum favours further upside here.
In 2030, CGTX is projected to trade between $0.9744 and $2.30, averaging $1.44 — a potential gain of +62% from today's $0.8896. That is up +24% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cognition Therapeutics, Inc.'s 2031 outlook centres on $1.74, within a $1.14 to $2.86 range. That is up +21% on the projected 2030 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2032, CGTX could reach as high as $3.41, with a base case around $2.02 and support toward $1.29 — roughly +127% from $0.8896. Buyers look set to stay in control over this stretch.
Expect CGTX to range from $1.29 to $3.59 through 2033. The $2.08 average target implies a +133% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The CGTX price prediction for 2034 points to an average of $2.19 (low $1.33, high $3.88) — a potential gain of +147% on today's $0.8896. Buyers look set to stay in control over this stretch.
In 2035, CGTX is projected to trade between $1.30 and $3.97, averaging $2.20 — a potential gain of +148% from today's $0.8896. That is up 0% on the projected 2034 average. Momentum favours further upside here.
Cognition Therapeutics, Inc.'s 2040 outlook centres on $3.81, within a $1.99 to $7.44 range. That is up +73% on the projected 2035 average. That marks a +328% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGTX could reach as high as $14.61, with a base case around $6.66 and support toward $3.00 — roughly +649% from $0.8896. Momentum favours further upside here.
Investing $1,000 in CGTX today (≈ 1,124.100719 CGTX) could be worth
$7,485.87
+$6,485.87 (+649%) by 2050 · US Dollar
Based on the average projected CGTX price of $6.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGTXwould be worth at today's price.
$1,000 invested in CGTX on Jul 31, 2025 (≈ 1,706.484568 CGTX) would be worth
$1,518.09
+$518.09 (+51.8%) today · 1.52× · US Dollar
Based on a CGTX entry price of $0.586 vs. today's $0.8896.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.92 | $966.96 | -3.3% |
| 1 month ago | $1.13 | $787.26 | -21.3% |
| 3 months ago | $1.28 | $695 | -30.5% |
| 6 months ago | $1.14 | $780.35 | -22.0% |
| 1 year ago | $0.586 | $1,518.09 | +51.8% |
| All time (4.8y) ago | $12.77 | $69.66 | -93.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGTX forecast.
Our base-case forecast reaches $1.80 around 2032.
Implied market cap at $1.80: $161.1M
The multi-year forecast paints a bullish trajectory, with notable upside starting in the late 2020s and continuing through 2050. In 2029, the avg is $1.37 with a max of $2.28 and ROI of 44.4% under a bullish outlook. By 2030 the avg rises to $1.72 with a max of $2.99 and ROI of 81.7% as sentiment remains bullish.
Looking further out, the 2040 forecast shows an avg of $5.09 with a max of $11.17 and ROI of 436.1%, while the 2050 forecast projects an avg of $9.14 with a max of $21.01 and ROI of 862.6% in a bullish scenario.
These figures illustrate potential upside over the long term, but they are estimates and not guarantees. Market conditions, clinical results, regulatory developments, and other factors can drive outcomes differently than projected.
Tap a question to reveal the answer.
Min $1.07, Avg $1.72, Max $2.99, ROI 81.7%, Sentiment BULLISH.
Forecasts show bullish sentiment from 2029 through 2050 with an Avg of $9.14 and ROI of 862.6% by 2050, but these are estimates and not guaranteed.
Yes—the 2032 forecast lists Min $1.49, Avg $2.63, Max $4.87 with ROI 177 and a BULLISH sentiment.
Current price is $0.9491; market cap is $84.94M.
Min $2.29, Avg $5.09, Max $11.17, ROI 436.1%, Sentiment BULLISH.
Cognition Therapeutics, Inc. Community Discussion
0Share your Cognition Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.